It has been reported that downregulation of miR-101 contributes to cisplatin resistance of non-small cell lung cancer cells by targeting ROCK2 [36], miR-101 sensitizes liver cancer cells to doxorubicin-induced cell death through targeting Mcl-1 [38], and miR-101 can enhance chemosensitivity in epithelial ovarian cancer [34]. Here, ROCK2 is linked to liver cancer.